HOPKINTON, Mass., April 2 /PRNewswire-FirstCall/ -- Caliper Life Sciences, Inc. today announced that John DelliSanti has joined the company as executive vice president and chief commercial officer. In this position, Mr. DelliSanti will lead Caliper’s Commercial Operations which include the company’s worldwide sales, marketing and services efforts.
As executive vice president and chief commercial officer, Mr. DelliSanti will be responsible for furthering Caliper’s overall customer relationships and product penetration into all research and development markets that the company serves. He has a proven track record for growing “top line”, while improving profitability and competitiveness for product lines ranging from capital equipment to services, including reagents.
“John is a great addition to our team at an important moment. Our strategic footprint is complete and his strong capabilities and experience are a perfect match to lead our commercial operations and deliver the strong growth and margin improvement that we foresee,” said Kevin Hrusovsky, president and CEO of Caliper.
“Caliper is an innovative company that is well positioned to impact the productivity of drug discovery,” said DelliSanti. “This is an exceptional moment in Caliper’s evolution to use my experience to drive adoption of the company’s exciting line up of technologies, services and reagents to streamline drug discovery and increase shareholder value.”
Prior to joining Caliper, Mr. DelliSanti led the Americas Commercial Operations at Invitrogen Corporation. During his career, he helped manage the integration of multiple acquisitions into commercial organization; this experience will be vital as Caliper continues to align product and services offerings to meet customer needs. In addition to serving as an executive at Invitrogen Corporation, Mr. DelliSanti held several positions at Accelrys, a leading chemistry software and informatics company. During his 12 year tenure, he rapidly accelerated through the ranks to lead the worldwide sales and services efforts managing more than 200 employees. Mr. DelliSanti began his professional career at Wyeth Pharmaceuticals and then Hitachi Instruments. He earned his M.B.A and B.S. in Chemistry from Fordham University.
About Caliper Life Sciences
Caliper Life Sciences is a leading provider of drug discovery and life sciences research solutions for the pharmaceutical and biotechnology industries. With its recent acquisitions of NovaScreen Biosciences and Xenogen Corp., Caliper has positioned itself to transform drug discovery and development through a keen focus on clinically relevant experimentation. Caliper’s products and services, assembled from a leading portfolio of microfluidics, liquid handling, and imaging technologies, span in vitro and in vivo experimentation and address key issues on the critical path of drug discovery and development. More information about Caliper can be found at www.caliperLS.com.
NOTE: Caliper is a registered trademark of Caliper Life Sciences, Inc.
Caliper Life Sciences, Inc.
CONTACT: Renee Zeppetello of Caliper Life Sciences, +1-410-567-9337, orRenee.Zeppetello@novascreen.com; or Stacey Holifield of SchwartzCommunications, +1-781-684-0770, or caliper@schwartz-pr.com
Web site: http://www.caliperLS.com//
